Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection  by Ashton-Chess, Joanna et al.
Immunoproteasome beta subunit 10 is increased in
chronic antibody-mediated rejection
Joanna Ashton-Chess1,2,3,8, Hoa Le Mai1,2,3,8, Vojislav Jovanovic1,2,3,8, Karine Renaudin4,
Yohann Foucher1,2,3, Magali Giral1,2,3, Anne Moreau4, Emilie Dugast1,2,3, Michael Mengel5,
Maud Racape´1,2,3, Richard Danger1,2,3, Claire Usal1,2,3, Helga Smit1,2,3, Marina Guillet6, Wilfried Gwinner7,
Ludmilla Le Berre1,2,3, Jacques Dantal1,2,3, Jean-Paul Soulillou1,2,3,8 and Sophie Brouard1,2,3,8
1INSERM, U643, Nantes, France; 2CHU Nantes, Institut de Transplantation et de Recherche en Transplantation, ITERT, Nantes,
France; 3Faculte´ de Me´decine, Universite´ de Nantes, Nantes, France; 4CHU Nantes, Service d’Anatomie Pathologique, Nantes,
France; 5Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada; 6TcLand Expression,
Nantes, France and 7Abteilung fu¨r Nephrologie, Medizinische Hochschule Hannover, Hannover, Germany
Chronic active antibody-mediated rejection is a form of late
rejection with a poor prognosis. To identify specific markers
of this, we analyzed several microarray studies in the
literature and performed mRNA profiling of 65 biopsies and
165 blood samples of a large cohort of renal transplant
patients with precisely characterized pathologies.
Immunoproteasome beta subunit 10 was found to be
specifically increased in the graft and blood samples during
chronic active antibody-mediated rejection and was also
significantly increased in rat cardiac allografts undergoing
acute rejection as well as chronic active antibody-mediated
rejection. This syndrome is characterized by chronic
transplant vasculopathy associated with diffuse C4d staining
and circulating donor-specific antibodies. Using this animal
model, we found that administration of the proteasome
inhibitor, Bortezomib, delayed acute rejection and
attenuated the humoral response in both the acute phase
and established state of this syndrome in a dose-dependent
manner. Following treatment with this reagent, donor-
specific antibodies and C4d deposition were reduced.
These studies highlight the role of the proteasome in chronic
rejection and identify this molecule as a marker of this
syndrome.
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Long-term graft loss remains the bane of kidney transplanta-
tion. More recently, much attention has been paid to the
‘humoral’ theory of chronic allograft rejection.1 Evidence for
the involvement of a humoral arm of the immune response
to allografts has come from studies analyzing the impact of
anti-human leukocyte antigen (HLA) antibodies on graft
outcome,2,3 and evidence of complement cascade activation
within kidney grafts diagnosed by intragraft deposition of the
complement split product C4d.4,5 These data were recently
reinforced when the definition of chronic active antibody-
mediated rejection (CAMR) was introduced into the Banff
classification of kidney graft injury as an association of
specific histological lesions associated with diffuse C4d
deposition in peritubular capillaries and circulating donor-
specific anti-HLA (DSA) antibodies.6
Current therapies to combat the acute form of antibody-
mediated rejection aim to reduce antibody titers through
the use of intravenous immunoglobulin,7 plasmapheresis,8 or
B-cell-targeting antibodies such as Rituximab,9 but these
have not gained notoriety in the chronic form. Moreover,
these strategies do not seem to have an effect on plasma cells,
the source of antibodies. Thus, the development of more
effective strategies would benefit patients suffering from this
type of late graft rejection with such a poor prognosis.10 The
identification of molecular markers associated with
CAMR would not only facilitate its diagnosis, but could also
help to understand the pathophysiology of CAMR and thus
aid in the design of new therapeutic strategies. Currently,
CAMR diagnosis depends on the triad of graft lesions
together with intragraft C4d and DSA mentioned above.
Neither one of these alone can diagnose CAMR; DSA are
predictive of graft loss but have not yet been shown to
tightly correlate with intragraft lesions, and C4d has
recently been shown to be absent in up to 50% of CAMR
cases.11 Here, using a gene-set comparison approach, we
describe the identification of a well-known molecule, the
immunoproteasome-b subunit 10 (PSMB10, also known as
MECL-1) as a potential marker of CAMR in humans.
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Moreover, we obtained concordant results in a rat heart
allograft model that we have recently described as a
pertinent model of CAMR (histological lesions of chronic
vascular damage, persisting antidonor antibodies and diffuse
C4d deposits on the graft vasculature).12 Here we show that,
in this model, inhibition of the proteasome significantly
prolongs allograft survival by preventing acute rejection, and
also attenuates established humoral immune responses
(decreases DSA and C4d deposition) in both short- and
long-term surviving recipients. Our data suggest the
implication of the immunoproteasome in CAMR with
PSMB10 as a potentially useful marker and point toward
proteasome inhibition as a means of treating both acute
rejection and CAMR.
RESULTS
Identification of the inducible member of the
immunoproteasome, PSMB10, as a potential intragraft
biomarker of chronic graft injury in human kidney
transplantation
In order to identify potential diagnostic markers of chronic
graft injury in humans, we compared several microarray data
sets published in the literature in the context of human
kidney transplant biopsies with chronic lesions (referred to as
CAN or chronic rejection in the studies in question; Table 1).
In total, less than 20 molecules were found to be common
between at least two data sets (not shown). Among them,
PSMB10 was found to be upregulated in chronic rejection in
a study by Donauer et al.13 and in Banff grade 3 versus Banff
grade 0 in a study by Flechner et al.14 PSMB10 was chosen
from among the others because of its function as an
instrumental member of the immunoproteasome and the
availability of reagents to test it as a potential therapeutic
target. In fact, the immunoproteasome was shown to be
involved in antigen processing for presentation,15 and
proteasome inhibition was shown to blunt antibody
responses in mice.16 In healthy individuals, PSMB10 is
expressed constitutively by the immune system (the spleen,
peripheral blood, and lymph nodes; Supplementary
Figure S1A) and by lymphocytes and monocytes, where its
expression is regulated by cell activation (Supplementary
Figure S1A and B). It can also be induced through exposure
to interferon-g.17
PSMB10 is upregulated in CAMR in human kidney transplant
recipients
We analyzed PSMB10 in graft biopsies with different
histological diagnoses (Table 2). As shown in Figure 1a,
PSMB10 mRNA was specifically upregulated in biopsies with
CAMR (Po0.001). Of note, PSMB10 expression was not
correlated with proteinuria (r¼0.16; P¼ 0.63). Receiver
operator characteristic (ROC) curve analysis revealed that
PSMB10 mRNA had an excellent capacity to discriminate
CAMR from the other histological diagnoses, with an area
under the curve of 0.92 (Po0.0001, 95% confidence interval
of 0.84–0.97). At a cut-off of 1.95, there was a sensitivity of
0.85 and a specificity of 0.83 (Figure 1b). Thus, PSMB10
shows potential as an intragraft marker of CAMR in humans.
Given that ACR is becoming a rare phenomenon, we next
focused on CAMR, to determine whether the specific
regulation of PSMB10 was reflected in the peripheral blood.
PSMB10 was analyzed in 150 kidney transplant recipients
with stable graft function and 15 patients with CAMR
(Table 3). As shown in Figure 2, patients with CAMR had
significantly higher levels of PSMB10 than those with stable
graft function (Po0.01). Again, PSMB10 expression was not
correlated with proteinuria (r¼0.01; P¼ 0.98).
To assess whether PSMB10 could potentially serve as a
minimally invasive clinical decision-making tool, ROC curve
analysis was performed. The results (Figure 2b) showed that
this molecule analyzed in recipient blood could still
discriminate CAMR from the other groups of patients well,
albeit less than in the biopsies, with an area under the curve
of 0.72 (Po0.01; 95% confidence interval of 0.57–0.84). At a
cut-off of 0.96, there was a sensitivity of 0.67 and a specificity
of 0.64.
Potential confounding factors influencing the expression of
PSMB10
We next performed a multivariate analysis on the 150 stable
patients to evaluate the potential impact of clinical and
demographic factors on the expression of PSMB10 in the
peripheral blood (Table 3). Of all the parameters tested
(legend to Figure 2), the statistically significant parameters
identified as being associated with PSMB10 mRNA expre-
ssion were recipient gender (Po0.05) and time post-
transplant (Po0.01). Thus, creatinine clearance, proteinuria,
Table 1 | Studies used to identify common biomarkers of late graft injury
First author, journal/year Subject Sample Microarray platform Gene list
Hotchkiss, Transplantation/2006 ‘Chronic allograft
nephropathy’ (CAN)
Biopsies Affymetrix Selected upregulated genes in CAN (gene list
published)
Flechner, Am J Transplant/2004 Banff grade 3 vs Banff 1 Biopsies Affymetrix Genes upregulated in Banff 3 vs Banff 01 (gene list
available on the authors’ website)
Scherer, Transplantation/2003 ‘Chronic Rejection’ (CR) Biopsies Affymetrix Genes upregulated in biopsies at 6 months which
went on to develop CR at 1-year vs biopsies at
6 months with no CR at 1-year (exhaustive gene
list kindly provided by the authors)
Donauer, Transplantation/2003 ‘Chronic Rejection’ (CR) Biopsies ‘Homemade’ according
to Stanford protocol
Upregulated in CR vs normal and polycystic
kidneys (gene list published)
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donor and recipient age, number of HLA incompatibilities
(AþBþDR), and maintenance immunosuppression were
not confounders, neither were presence or absence of anti-
HLA. Thus, PSMB10 is not simply a reflection of presence of
anti-HLA antibodies. These data are modeled in Figure 2c,
where predicted values of PSMB10 are expressed according to
time post-transplant and recipient gender. PSMB10 was thus
significantly higher in the peripheral blood mononuclear cells
(PBMCs) of male recipients compared with female recipients
(Po0.05) and displayed a distinctive inverse bell-shaped
relationship with time post-transplant. However, these
potentially confounding factors could not explain the
difference in PSMB10 between stable (STA) and CAMR,
because there was no difference in time post-transplant or
recipient gender between the STA and CAMR groups
(P¼not significant). Thus, overall these data show that
PSMB10 may also be a peripheral blood biomarker of CAMR
in humans, but some potential confounding factors may exist
and need to be taken into consideration.
PSMB10 as an intragraft and peripheral blood marker of
acute rejection as well as CAMR in a rat cardiac allograft
model
To determine whether we could reproduce the above data in a
rodent model, PSMB10 mRNA was analyzed in the grafts and
PBMCs of rat recipients of cardiac allografts undergoing
acute rejection or CAMR. We found that PSMB10 was
significantly increased in the cardiac allografts during both
acute rejection (at day (D)7 post-transplant) and CAMR
(analyzed at D100 post-transplant) compared with syngeneic
controls (Figure 3a; Po0.01 and Po0.0001, respectively).
A different expression profile was observed in the PBMCs,
where PSMB10 displayed no change during acute rejection,
suggesting an effect of DST priming on PBMCs. Moreover,
similar to in humans, a significant increase was observed
during CAMR at D100 post-transplant (Figure 3b; Po0.05).
Thus, PSMB10 shows potential as an intragraft and
peripheral blood marker of CAMR in rats and humans.
The proteasome as a therapeutic target for AR: prolonged
survival and attenuation of the humoral response during AR
in a rat cardiac allograft model upon immunoproteasome
inhibition with Bortezomib
Given this upregulation of PSMB10 in acute rejection and
CAMR in this rodent model, we set out to determine whether
proteasome inhibition could influence graft outcome. In the
context of acute rejection, recipients of major histocompa-
tibility complex (MHC)-mismatched cardiac allografts were
treated with Bortezomib every other day from D0–D20. The
data presented in Figure 4a show that Bortezomib dose-
dependently prolonged cardiac allograft survival with an
optimal effect at 0.1 mg/kg, giving a mean survival of 31.7
days (n¼ 6) (versus 6.3 days in untreated controls (n¼ 4);
Po0.01). Moreover, at D7, there were significantly lower
circulating anti-donor MHC class I and II antibodies for total
immunoglobulin G (IgG) (Po0.01) as well as IgG1
(Po0.01), and IgG2c (Po0.05), with no reduction for
IgG2a or IgG2b (Figure 4b).
The proteasome as a therapeutic target for CAMR:
attenuation of the humoral response during CAMR in a rat
cardiac allograft model upon immunoproteasome inhibition
with Bortezomib
In the context of CAMR, Bortezomib was initially adminis-
tered every other day from D80 to D100 at 0.1 mg/kg in rat
recipients of cardiac allografts that had received DST before
Table 2 | Patients included in analysis of biopsies (Nantes and Hanover biopsies pooled; see Materials and Methods section).
Group N IF/TA CNI tox CAMRa ACRb
n 13 16 14 13 9
Recipient age, years: median (range) 40.0 (18–69) 49.5 (24–66) 51.5 (29–66) 48 (24–71) 45 (25–61)
Recipient gender ratio (M/F) 9:4 9:7 8:6 7:6 5:4
Donor age, years: median (range) 35.0 (12–69) 51.0 (23–77) 41.5 (16–56) 34 (14–75) 34 (5–72)
Time post-transplant years: median (range)c 1 2 (1–3) 5 (1–11) 11 (1–18) 0.67 (0.08–5)
Donor gender ratio (M/F) 8:5 10:6 8:6 5:6 (n=2 NA) 8:1
HLA incompatibilities: mean±s.d. 2.5±1.7 2.5±1.2 2.4±1.4 3.5±1.4 3.1±1.1
% First transplant 100 100 79 92 78
Cockroft creatinine clearance (ml/min): mean±s.d. 75.9±26.4 49.9±17.0 52.4±24.1 25.8±16.7 32.6±16.2
Proteinuria (g/24 h): median (range) 0.10 (0.03–0.43) 0.11 (0.01–6.37) 0.09 (0.03–4.47) 1.94 (0.80–4.00) 0.46 (0.21–0.49)
Banff c grade: mean±s.d. 0.00±0.00 1.25±0.58 0.80±1.03 2.27±0.79 1.5±0.53
Immunosuppression protocol (% of patients) MMF: 69% MMF: 63% MMF: 64% MMF:46% MMF: 78%
at the time of biopsy Aza: 8% Aza: 13% Aza: 14% Aza: 15% Aza: 0%
FK506: 62% FK506: 63% FK506: 29% FK506:38% FK506: 67%
CsA: 23% CsA: 13% CsA: 71% CsA: 54% CsA: 0%
Rapa: 0% Rapa: 13% Rapa: 7% Rapa: 0% Rapa: 22%
Steroids: 54% Steroids: 69% Steroids: 57% Steroids: 23% Steroids: 33%
Abbreviations: ACR, acute cellular rejection; Aza, azathioprine; CAMR, chronic antibody-mediated rejection; CNI tox, calcineurin inhibitor toxicity; CsA, cyclosporin A;
FK 506, tacrolimus; DSA, donor-specific anti-HLA; HLA, human leukocyte antigen; IF/TA, interstitial fibrosis and tubular atrophy; MMF, mycophenolate mofetil; N, normal
histology; TG, transplant glomerulopathy.
aThe DSA were directed against class II (n=6), class I (n=2), or both (n=5).
bThese were grade Ia (n=3), Ib (n=2), and grade IIa (n=4 with moderate intimal arteritis-vi) – all were C4d-negative and DSA-negative.
cBiopsies for cause only.
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transplantation and were surviving long-term. The
DSTþBortezomib recipients had significantly reduced levels
of circulating anti-donor MHC class I and II antibodies
for total IgG as well as IgG1, IgG2a, IgG2b, and IgG2c
(Figure 5a). Bortezomib-treated recipients tended to display
less intra-graft complement deposition (Table 4). In fact,
although the grafts of DST-treated animals displayed diffuse
linear expression of C4d (Figure 5b, left-hand panel and
magnified insert), two Bortezomib-treated animals showed
only vague background staining, whereas the others displayed
minimal staining (Figure 5b, right-hand panel and magnified
insert). There were no differences between the two groups in
terms of infiltrate, fibrosis, vascular obstruction, vascular
lesions, and number of affected arteries; however, myocyte
necrosis was absent in four of the five animals in the
Bortezomib-treated group (Table 4 and examples in Figure
5c, far left and middle panels). We thus performed further
experiments in which treatment was initiated earlier at D60
and continued until D100. Again, a significant decrease in
circulating anti-donor MHC class I and II antibodies for total
IgG as well as for three of the four IgG subtypes tested was
noted at D100 post-transplant in the Bortezomib-treated
recipients (Figure 5d). This decrease was not simply a time-
dependent effect. because recipients had significantly less
DSA after the 40-day treatment versus before treatment,
whereas DSA levels were unchanged in untreated animals
over the same time period (Figure 5e). C4d staining at D100
in this group was heterogeneous (Table 4). A histological
analysis at D100 showed that there was a tendency toward
reduced vascular lesions and a significant reduction in
fibrosis compared with the untreated DST group (Po0.05;
Table 4 and an example Figure 5c, far right panel). Thus, in
this model and at the dose and schedules studied,
Bortezomib is able to significantly attenuate the humoral
immune response in graft recipients undergoing CAMR with
a reduction in fibrosis and a tendency to reduce the
histological lesions of transplant vasculopathy.
Finally, as PSMB10 expression did not correlate with
proteinuria in the blood or graft of humans, we wished to
confirm this in a rat model. For this purpose, we analyzed
PSMB10 in Buffalo/Mna rats, a well-known rat model of
proteinuria due to spontaneous idiopathic nephritic synd-
rome of unknown origin (see Materials and Methods
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Figure 1 |Differential expression of mRNA for the
immunoproteasome subunits PSMB10 and PSMB8 in renal
transplant biopsies and their capacity to diagnose acute and
chronic rejection. (a) Transcription of PSMB10 mRNA in renal
transplant biopsies displaying normal histology, interstitial fibrosis
and tubular atrophy (IF/TA) of unknown etiology, lesions
evocative of calcineurin inhibitor toxicity (CNI tox), acute cellular
rejection (ACR) and chronic antibody-mediated rejection (CAMR)
(see Materials and Methods for precise definitions). Results
represent pooled data for 6-month protocol biopsies and biopsies
taken at X1-year post-transplantation (similar results were found
for the two cohorts). Statistical significance according to a
Kruskal–Wallis test followed by a Dunn’s Multiple Comparison test
is indicated: ***Po0.001. PSMB10 mRNA was measured by
quantitative PCR using a TaqMan probe set (Hs00160620_m1).
Expression levels were calculated using the 2DDCt method
where the reference represents onefold expression, as previously
described.44 Hypoxanthine phosphoribosyl transferase
(Hs99999909_m1) was used as an endogenous control to normalize
RNA starting quantity. (b) Receiver operator characteristic (ROC)
curve analysis of PSMB10 in the combined 6-month and X1-year
biopsy cohorts; its capacity to discriminate CAMR from all the
other biopsies is analyzed.
Table 3 | Patients included in analysis of PBMCs
Group STA CAMRa
n 150 15
Recipient age in years: median
(range)
53 (20–85) 51 (29–76)
Recipient gender (% males) 62 47
Donor age in years: median (range) 36 (9–69) 41 (14–74)
Donor gender (% males) 75 60
Time post-transplant in years:
median (range)
8 (5–21) 6 (1–25)
HLA incompatibilities: mean±s.d. 3.4±1.3 3.5±1.7
% First transplantations 100 80
Cockroft creatinine clearance
(ml/mn): mean±s.d.
65.6±14.2 34.3±19.7
Proteinuria (g/24 h): median (range) 0.16 (0.04–0.16) 2.61 (1.95–11.52)
IS protocol at blood sampling MMF: 51% MMF: 60%
Aza: 26% Aza: 7%
FK506: 26% FK506: 67%
CsA: 72% CsA: 20%
Steroids: 15% Steroids: 27%
Abbreviations: Aza, azathioprine; CAMR, chronic antibody-mediated rejection; CNI,
calcineurin inhibitor; CsA, cyclosporin A; DSA, donor-specific antibody; FK 506,
Prograf; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; NA, not
applicable; PBMC, peripheral blood mononuclear cell.
aThe DSAs were directed against class II (n=11), class I (n=1), or both (n=3).
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section for details). As shown in the Figure 6, PSMB10 was
not significantly differentially expressed between rats with or
without proteinuria, despite radical differences in proteinuria.
DISCUSSION
Here we used a literature gene-set comparison approach and
identified PSMB10 as a potential biomarker of chronic graft
injury. Further profiling by quantitative PCR in biopsies and
PBMCs of renal transplant recipients revealed this molecule
to be specifically increased in the graft and blood in CAMR.
PSMB10 was also significantly increased in rat cardiac
allograft models with acute or chronic rejection. In the
acute model, administration of the proteasome inhibitor
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Figure 2 |Differential expression of PSMB10 mRNA in the
peripheral blood mononuclear cells of renal transplant
patients, its capacity to diagnose chronic rejection and its
interaction with confounding factors. (a) PSMB10 mRNA
expression in patients with stable graft function under standard
immunosuppression (STA; n¼ 150) and chronic antibody-mediated
rejection (CAMR; n¼ 15) (see Materials and Methods section for
precise definitions). Statistical significance according to a
Mann–Whitney test is indicated: **Po0.01. PSMB10 mRNA was
measured by quantitative PCR as described in the legend to
Figure 1. (b) Receiver operator characteristic (ROC) curve analysis of
PSMB10 in the PBMCs of renal transplant patients. The capacity of
PSBM10 to discriminate CAMR from the other transplant groups is
analyzed. (c) Results of a multivariate linear regression analysis on
log-transformed PSMB10 values. Statistical modeling of the
relationship between PSMB10 mRNA values, time post-transplant
and donor gender is illustrated. Parameters analyzed included
donor and recipient age and gender, time post-transplant,
creatinine clearance, proteinuria, number of HLA incompatibilities
(Aþ BþDR), presence or absence of anti-HLA, and maintenance
immunosuppression (presence/absence of steroids, high versus
low trough level CsA (o125 versus X125 ng/ml) versus high and
low trough level FK-506 (o5 versus X5 ng/ml).
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Figure 3 |PSMB10 mRNA profiles in the allografts and PBMCs
of rat recipients of MHC-mismatched heart grafts displaying
acute and chronic rejection. PSMB10 mRNA transcription in the
grafts and PBMCs of rat recipients of MHC-mismatched and
DST-treated or syngeneic cardiac transplants. Analyses were
performed at D5 and D100 post-transplant as well as during acute
rejection (mean 6.3 days post-transplant). PSMB10 was measured
by quantitative PCR as described in the legend to Figure 1 using
TaqMan probes for rat PSMB10 (Rn01432424_g1) and rat HPRT
(Rn01527838_g1). Statistical significance according to a
Kruskal–Wallis test followed by a Dunn’s Multiple Comparison test
is indicated: ***Po0.001; **Po0.01 and *Po0.05. In this model,
DST treatment induces long-term survival but with histologic
lesions of chronic transplant vasculopathy40 associated with
deposition of the complement split product C4d and circulating
donor-specific antibodies.12
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Bortezomib not only dose-dependently delayed acute rejec-
tion but also attenuated the humoral response. In the chronic
model with established CAMR, Bortezomib treatment
decreased DSA and C4d deposition and improved some
aspects of the chronic tissue injury. These data thus suggest
PSMB10 as a potential marker and the proteasome as a
therapeutic target for CAMR.
Proteasomes are large protease complexes located in
cytoplasm and nuclei that degrade cellular proteins in a
ubiquitin-dependent and adenosine triphosphate-dependent
manner present in immune cells.18 In response to interferon-g,
the three catalytic subunits are replaced by their homologous
subunits, PSMB 8, 9, and 10, to form the so-called
immunoproteasome, which is essential for processing anti-
genic peptides for presentation through the class I MHC
complex.15 Immunoproteasomes have additional effects that
are independent to class I processing, for example, they
inhibit T-cell proliferation, as T cells lacking immunoprotea-
some subunits hyperproliferate in vitro and in vivo, and KO
mice have higher numbers of central memory CD8þ cells.19
Experiments in KO mice have revealed that PSMB10 is
involved in controlling homeostatic equilibrium between
T-cell subsets,20 thereby controlling the T-cell repertoire.21
Given the expression of PSMB10 by lymphocytes and
monocytes, it is possible that the increase in PSMB10 in the
graft in CAMR may be the result of specific infiltration of
these cells. B cells in particular may be involved in this
because patients with chronic rejection undergo lymphoid
neogenesis with the development of intragraft B-cell germinal
centers.22 Likewise, increased PSMB10 expression may come
from locally present activated monocytes or mature dendritic
cells, as the immunoproteasome is known to be increased in
these cells.23 Given that the proteasome decreases during late
phase plasma cell differentiation,24 it is unlikely that the
increase in PSMB10 in the peripheral blood stems from an
increase in plasma cells in chronic rejection. ROC curve
analysis suggested that the level of PSMB10 in the blood of
graft recipients could be useful to diagnose CAMR, although
it may not be sufficient as a stand-alone marker and could be
combined with other markers to improve its diagnostic
performance. Moreover, we found PSMB10 levels to be
influenced by recipient gender and time post-transplant (but
not presence of anti-HLA or renal function), highlighting the
need to take confounding factors into account in biomarker
analyses. Thus, PSMB10 is not simply a reflection of DSA or
poor renal function, but rather of histological lesions
together with C4d and DSA. Future analyses on simultaneous
biopsy blood samples, which were not possible here because
of lack of material, could be considered to directly compare
intragraft and peripheral blood diagnostic performance.
The intragraft upregulation of PSMB10 we observed in
CAMR in both humans and rats prompted us to test the
proteasome inhibitor Bortezomib in the rat models of both
acute rejection and CAMR. Currently, Bortezomib is used in
the clinic for multiple myeloma and solid tumors.25 However,
a limited number of studies have analyzed the effect of this
drug on acute rejection in murine models of transplantation,
showing a preventative effect on both heart26 and islet27
allograft acute rejection. On the basis of blood biochemistry,
Bortezomib was also associated with side effects, but these
were reversible upon cessation of treatment.27 Our data in a
rat model of acute heart rejection are similar to those
reported in the mouse, with a similar survival prolongation
observed in both models. In the chronic model, diminution
of some aspects of chronic injury was observed. The
preventative effect on acute rejection is compatible with the
hypothesis that proteasome inhibition reduces alloantigeni-
city by reducing class I presentation. Moreover, we observed a
significant decrease in antibody production, suggesting an
attenuating effect on the humoral response. Very recent data
showed that proteasome inhibition specifically induces death
of activated T cells,28 and suppresses essential immune
function of CD4þ T cells upon activation by allogeneic
dendritic cells.29 Moreover, proteasome inhibition has been
shown to modulate toll-like receptor4-induced dendritic cell
activation,30 which could have a role here, as we recently
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Figure 4 | Induction treatment in rat recipients of
MHC-mismatched cardiac allografts with Bortezomib.
(a) Kaplan–Maier survival analysis of cardiac allograft recipients
untreated (K) or treated every other day for 20 days with
Bortezomib at 0.025 (’), 0.05 (m), or 0.1 (.) mg/kg. Statistical
significance is indicated **Po0.01. (b) Measurement (as described
in the Materials and Methods section) of anti-donor MHC class I
and II IgG1, IgG2a, IgG2b, and IgG2c subtypes in the serum of
MHC-mismatched cardiac allograft recipients at D7 post-
transplant treated with Bortezomib (D7-T) or without Bortezomib
treatment and thus undergoing rejection (D7-R). Results are
expressed as mean fluorescence intensity (MFI). Statistical
significance is indicated *Po0.05, **Po0.01.
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found toll-like receptor 4 to be increased in the graft and
blood of CAMR patients.31
We also found that in a rat model of CAMR, Bortezomib
decreased the humoral immune response by significantly
reducing DSA. These data are in accordance with a recent
report that proteasome inhibition blunts Ab responses
following in vivo B-cell activation in mice, by promoting
apoptosis.16 In the latter study, immunoproteasome sub-
components decreased during B-cell differentiation, in
parallel with increased immunoglobulin synthesis. More
recently, Bortezomib was shown to rapidly and efficiently
deplete both short- and long-lived plasma cells in the spleens
and bone marrow in a murine model of lupus-like disease,
leading to reduced autoantibody development.32 Moreover,
Bortezomib has recently been shown to induce apoptosis of
plasma cells, to block anti-HLA Ab secretion in vitro, and to
transiently decrease plasma cells in vivo in renal transplant
recipients.33,34 However, in the latter studies in humans,
Bortezomib was used in combination with other immuno-
suppressors and plasma exchange making it difficult to
pinpoint the specific role of Bortezomib among the treatment
arsenal. Moreover, its effect on graft histology has yet to be
determined. In our model, we show a clear-cut effect of
Bortezomib monotherapy on DSA and C4d, significantly
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Figure 5 |Maintenance treatment in rat recipients of MHC-mismatched cardiac allografts with Bortezomib. (a) Measurement
(as described in the Materials and Methods section) of anti-donor MHC class I and II total IgG and IgG1, IgG2a, IgG2b, and IgG2c subtypes in
the serum of MHC-mismatched cardiac allograft recipients treated with DST or with DST followed by Bortezomib from D80–D800, at D100
post-transplantation. Results are expressed as mean fluorescence intensity (MFI). Statistical significance is indicated: *Po0.05. (b)
Immunoperoxidase staining of C4d at D100 post-transplantation in recipients of MHC-mismatched cardiac allografts treated with DST
alone (left-hand panel and insert) or with DST followed by Bortezomib from D80 to D100 (right-hand panel and insert) (see Materials
and Methods section for details). (c) Histology (hematoxylin and eosin) at D100 post-transplantation in recipients of MHC-mismatched
cardiac allografts treated with DST alone (far left panel) or with DST followed by Bortezomib from D80 to D100 (middle panel) or from
D60 to D100 (far right panel) at  100 magnification. (d) Measurement (as described in the Materials and Methods section) of anti-
donor MHC class I and II total IgG and IgG1, IgG2a, IgG2b, and IgG2c subtypes in the serum of MHC-mismatched cardiac allograft recipients
treated with DST or with DST followed by Bortezomib from D60 to D100, at D100 post-transplantation. (e) Paired measurement of anti-
donor MHC class I and II total IgG at D60 and D100 in untreated recipients and recipients treated with Bortezomib from D60 to D100.
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reduced allograft fibrosis and a tendency toward reduced
vascular lesions. Therefore, early treatment with Bortezomib
may be pivotal to prevent irreversible chronic lesions. Further
analyses in a rodent model of kidney transplantation would
also be interesting, although for the moment there are no
true models of CAMR in the kidney. Indeed, in the Fischer to
Lewis kidney transplant model of chronic allograft nephro-
pathy (reviewed by Marco35), our own experience revealed
chronic pyelonephritis with no vascular lesions (data not
shown).
On the whole, our data point toward PSMB10 as a
potentially useful intragraft and peripheral blood marker for
CAMR, with immunoproteasome inhibition as a valuable
treatment strategy for antibody-mediated rejection.
MATERIALS AND METHODS
Gene-set comparison
With the aim of identifying relevant biomarkers of late graft
injury, we compared the gene sets from four microarray
studies of late kidney graft injury published in the
literature13,14,36,37 (see Table 1). To overcome the problem
of a single gene having numerous denominations, accession
numbers, and so on, all genes were converted into a single
common identifier, the ‘gene ID,’ using the gene ID
conversion tool available on the DAVID Bioinformatic
Resources 2006 website (http://www.david.abcc.ncifcrf.gov/
home.jsp). Gene IDs from the different studies representing
were sorted in Microsoft Excel and repeats of the same ID
identified.
Human kidney transplant recipients
Study groups. All patients who participated in this study
gave informed consent, and the study was approved by the
University Hospital Ethical Committee and the Committee
for the Protection of Patients from Biological Risks. The
study was performed on 65 biopsies and 165 blood samples.
Samples were included prospectively on the basis of
histological or clinical criteria.
(a) Biopsies were collected at two centers, Nantes, France
(n¼ 45) and Hanover, Germany (n¼ 20). Of the total
Table 4 | Histological analysis of DST-treated animals (D7 and D14 before transplantation) subsequently untreated or treated
every other day from D80 to D100 or from D60 to D100 (CAMR lesions already established) with Velcade at 0.1mg/kg
Rat Group
Graft
infiltrate Fibrosis Necrosis
Vascular
lesions
Vascular
obstruction
No. of affected
arteries (art/section) C4d
1 DST 2 3* + 2 2 3 (28) +++
2 DST 2 3 + 0 0 0 +++
3 DST 3 4* + 2 4 13 (16) +++
4 DST 2–3 2 + 2 1 1 (21) +++
5 DST 2–3 3 + 1 1 3 (19) +++
1 DST+Bortezomib D80–D100 2–3 3–4* + 1–3 4 13 (33) +
2 DST+Bortezomib D80–D100 2 3  2 4 8 (48) 
3 DST+Bortezomib D80–D100 1–2 3–4  0 0 0 
4 DST+Bortezomib D80–D100 1–2 3  2 4 7 (38) ++
5 DST+Bortezomib D80–D100 1–2 3*  1 1 2 (16) ++
1 DST+Bortezomib D60–D100 2 1* + 0 0 0 +++
2 DST+Bortezomib D60–D100 2–3 2* + 0 0 0 ++
3 DST+Bortezomib D60–D100 1–2 3 Focal 3 3 7 (31) +++
4 DST+Bortezomib D60–D100 2 1 Focal 1 1 3 (8) +++
5 DST+Bortezomib D60–D100 1–2 2  0 0 0 
6 DST+Bortezomib D60–D100 2 2 Focal 0 0 0. 
P=NS Po0.05 P=NS P=NS P=NS
Abbreviations: CAMR, chronic antibody-mediated rejection; DST, donor-specific antibody; NS, not significant.
Infiltrate was graded from 0 to 4 (0, absence; 1, minimum; 2, discrete; 3, moderate; 4, abundant). Fibrosis was graded from 0 to 4 (0, absence; 1, focal; 2, diffuse-minimal; 3,
diffuse-moderate; 4, diffuse-abundant; *, edema). Vascular obstruction was graded from 0 to 4 (0, 0; 1,o20%; 2, 20–50%; 3, 50–80%; 4,480%). Vascular lesions were graded
from 0 to 3 (0, normal; 1, leuco-intimal adhesion; 2, inflammatory endarteritis; 3, fibrous endarteritis). C4d was graded from – to +++ (,o20%; +, 20–50%; ++, 50–75%, and
+++, 475%). Necrosis was graded as presence (+) or absence () of myocyte damage. Statistical significance was measured using a non-parametric Kruskal–Wallis test with
Dunn’s Multiple Comparison test.
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Figure 6 |PSMB10 and proteinuria in a rat model of idiopathic
nephritic syndrome. Proteinuria (left-hand graph) and
PSMB10 expression (right-hand graph) in Buffalo/Mna rats
at 1-month of age and 6 months of age (see Materials and
Methods section for details).
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65 biopsies, 29 were protocol biopsies at 6 months or
1 year and the remaining 36 were biopsies for cause.
All were classified according to the updated Banff
classification criteria,6 as displaying normal histology
(N- C4d-negative and DSA-negative; n¼ 13) or lesions
of interstitial fibrosis and tubular atrophy of unknown
etiology (IF/TA-C4d-negative and DSA-negative; n¼ 16)
or lesions of calcineurin inhibitor toxicity (tox-C4d-
negative and DSA-negative; n¼ 14), or lesions of acute
cellular rejection (ACR; n¼ 9) or CAMR (defined by the
presence of circulating DSA associated with transplant
glomerulopathy and deposition of C4d in peritubular
capillaries (n¼ 13). C4d staining was performed on
frozen sections with 450% staining being considered as
positive. The demographic and clinical data for all of
these patients are provided in Table 2.
(b) Peripheral blood mononuclear cells (PBMCs) were prepared
from the blood of 165 kidney transplant patients (largely
independent from those included in the biopsy analysis)
whose statuses were defined on a histological and/or
clinical basis: Stable graft function (patients under
standard immunosuppression with stable graft function
(creatinemia o150mmol/l and proteinuria o1 g/24 h for
at least 3 years including over the two previous 6-month
follow-up appointments with o20% change between the
two time points: STA; n¼ 150), or CAMR as defined
above (n¼ 15). The demographic and clinical data for
these patients are provided in Table 3.
Rodent transplant models
Study groups. Inbred male adult rats (200–250 g) of the
LEW.1A (RT1a) and LEW.1W (RT1u) MHC-incompatible
congeneic strains were purchased from Janvier (Le Genest-
Saint-Isle, France) and maintained in an animal facility under
standard conditions according to the European and Institu-
tional Guidelines.
(a) Acute rejection of heart allografts. LEW.1A rats received
heterotopic heart allografts from LEW.1W donors as
previously described38 and received no immunosuppres-
sive treatment. Rejection (cessation of heart beating
assessed by daily abdominal palpation) occurs at a mean
of 6.3 days post-transplant.
(b) Chronic antibody-mediated rejection of heart allografts.
LEW.1A rat recipients were transfused intravenously
with 1 ml of blood from a LEW.1W donor 14 and 7 days
before heterotopic LEW.1W cardiac transplantation as
described.39 Graft function was evaluated as above. In
this strain combination, donor-specific transfusion
induces long-term graft survival but does not inhibit
the indirect pathway of allorecognition, resulting in
histological lesions of chronic transplant vasculopathy40
associated with deposition of the complement split
product C4d and circulating DSAs.12
(c) Bortezomib treatment for the prevention of acute rejection.
Heart allograft recipients received Bortezomib (Velcade,
Millennium Pharmaceuticals, Cambridge, MA, USA)
intraperitoneally from the day of transplantation and
every other day until day (D) 20. Three different doses
were tested: 0.025, 0.05, and 0.1 mg/kg.
(d) Bortezomib treatment of CAMR in the context of DST-
induced long-term allograft survival. Heart allograft
recipients were treated with DST as described above
and received Bortezomib intraperitoneally at 0.1 mg/kg
every other day either from D80 until D100 or from D60
until D100. At this time, all allografts present vascular
lesions with diffuse C4d deposits and circulating
anti-DSA.
Rodent proteinuria model
The Buffalo/Mna rat strain maintained in our laboratory was
provided by Dr Saito (Central Experimental Institute,
Nokawa, Kawasaki, Japan). These rats have spontaneous
idiopathic nephritic syndrome of unknown origin as
previously described.41 They do not have proteinuria at
1 month of age but develop significant proteinuria by 6
months of age. Animal care was in accordance with our
institutional guidelines. The rats were placed in metabolic
cages for 24 h and total urinary protein concentration
(g/l) was measured by a colorimetric method using a Hitachi
autoanalyzer (Boehringer, Reims, France). Proteinuria
was expressed according to the formula proteinuria
(g/mmol)¼ urinary proteins (g/l)/urinary creatinine (mmol/l),
and it was considered to be abnormal at values 40.2 g/mmol.
Sample preparation
Human kidney transplant biopsies were processed as de-
scribed.42 Rat heart transplant or kidney tissue was processed
as described.40 Human and rat peripheral blood was collected
in EDTA vacutainers and PBMCs separated by density
centrifugation using Lymphosep, lymphocyte separation media
(Bio West, Nuaille, France). PBMCs were stored in TRIzol
(Invitrogen, Cergy Pontoise, France) at 801C until use.
RNA extraction and reverse transcription. Human biopsies
were processed as described in detail.42 Rat heart allografts
and rat and human PBMCs were processed using the TRIzol
method (Invitrogen) according to the manufacturer’s in-
structions. RNA quality and quantity was determined using
an Agilent 2100 BioAnalyzer (Palo Alto, CA, USA). Genomic
DNA was removed by DNase treatment (Roche, Indianapolis,
IN, USA). RNA was reverse transcribed into cDNA using
polydT oligonucleotide and Maloney leukemia virus reverse
transcription (Invitrogen).
Real-time quantitative PCR. Real-time quantitative
PCR was performed in an Applied Biosystems GenAmp
7700 sequence detection system (Applied Biosystems,
Foster City, CA, USA) as described in detail,42 using
commercially available primer and probe sets (Applied
Biosystems).
Rat cardiac allograft histological analyses and C4d immuno-
staining. Heart allografts were prepared as described by
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Ballet et al.12 and analyzed by a pathologist (KR) (see also
Table 4 and legend). C4d deposition was localized as
described by Ballet et al.12 using an affinity-purified
polyclonal rabbit antibody to C4d kindly provided by
Baldwin and group43 (department of pathology, John
Hopkins Medical Institutions, Baltimore, MD, USA).
Measurement of circulating anti-donor antibodies in rat
recipients of cardiac allografts. Anti-donor class I and II total
IgG and subtypes in the sera of untreated or Bortezomib-
treated recipients at D7 post-transplantation, and in DST-
treated and DSTþ Bortezomib-treated animals at D60 and
D100 post-transplantation were measured as described by
Ballet et al.12
Statistical analyses
The non-parametric Mann–Whitney test was used for
comparison between two groups. Note that there was an
imbalance in sample size between the CAMR and STA
patients (n¼ 15 versus 150); this was because we preferred to
use all available STA samples to better reflect the relatively
low prevalence of CAMR and to use all samples that were
used for the other analyses (multivariate analyses and
ROC). Such an imbalance is authorized within the context
of the non-parametric Mann–Whitney test. The non-para-
metric Kruskal–Wallis test was performed for comparison of
three or more groups, followed by Dunn’s multiple
comparisons test. ROC curve analysis was performed to
determine the cut-off point of PSMB10 in biopsies and/or
blood that yielded the highest combined sensitivity and
specificity in diagnosing CAMR (see Figure 1 legend for
explanation). Note that the n¼ 15 CAMR were compared
with a large number of STA patients (n¼ 150) in order to
better reflect the relatively low prevalence of CAMR in this
diagnostic test. The effect of the different clinical and
demographic parameters on the expression of PSMB10 in
patients with stable graft function, a multivariate linear
regression analysis, was performed following log transforma-
tion of the data taking into account the various parameters
(see legend to Figure 2). The statistical software used was
GraphPad prism 5.
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